Proton pump inhibitors alter the composition of the gut microbiota
暂无分享,去创建一个
Tim D Spector | Claire J Steves | Jordana T Bell | Angela C. Poole | Ruth E Ley | T. Spector | J. Bell | M. Jackson | C. Steves | R. Ley | Julia Goodrich | D. Freedberg | J. Abrams | Jessica L. Sutter | Maria-Emanuela Maxan | Daphne K. Welter | Daniel E Freedberg | Julian A Abrams | Matthew A Jackson | Julia K Goodrich | Maria-Emanuela Maxan | Angela C Poole | Jessica L Sutter | Daphne Welter
[1] T. van der Poll,et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia , 2015, Gut.
[2] Nora C. Toussaint,et al. Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. , 2015, Gastroenterology.
[3] P. Schloss,et al. Antibiotic-Induced Alterations of the Murine Gut Microbiota and Subsequent Effects on Colonization Resistance against Clostridium difficile , 2015, mBio.
[4] H B Xu,et al. Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. , 2015, Genetics and molecular research : GMR.
[5] Masahira Hattori,et al. Influence of Proton-Pump Inhibitors on the Luminal Microbiota in the Gastrointestinal Tract , 2015, Clinical and Translational Gastroenterology.
[6] D. Leffler,et al. Clostridium difficile infection. , 2015, The New England journal of medicine.
[7] D. Ward,et al. 16S community profiling identifies proton pump inhibitor related differences in gastric, lung, and oropharyngeal microflora. , 2015, The Journal of pediatrics.
[8] Reshma Aziz Merchant,et al. Proton pump inhibitors: Are we still prescribing them without valid indications? , 2014, The Australasian medical journal.
[9] N. Chia,et al. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility , 2014, Microbiome.
[10] Angela C. Poole,et al. Human Genetics Shape the Gut Microbiome , 2014, Cell.
[11] Uri Gophna,et al. Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors. , 2014, Environmental microbiology.
[12] D. Bates,et al. Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.
[13] Alireza Moayyeri,et al. COHORT PROFILE Cohort Profile : TwinsUK and Healthy Ageing Twin Study , 2013 .
[14] P. Siersema,et al. Proton pump inhibitor therapy predisposes to community‐acquired Streptococcus pneumoniae pneumonia , 2012, Alimentary pharmacology & therapeutics.
[15] D. Sinderen,et al. Gut microbiota composition correlates with diet and health in the elderly , 2012, Nature.
[16] D. Adler,et al. Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis , 2012, The American Journal of Gastroenterology.
[17] R. Cavallazzi,et al. Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis , 2012, The American Journal of Gastroenterology.
[18] Curtis Huttenhower,et al. Microbial Co-occurrence Relationships in the Human Microbiome , 2012, PLoS Comput. Biol..
[19] Katherine H. Huang,et al. Structure, Function and Diversity of the Healthy Human Microbiome , 2012, Nature.
[20] J. Heidelbaugh,et al. Overutilization of proton-pump inhibitors: what the clinician needs to know , 2012, Therapeutic advances in gastroenterology.
[21] L. Wiseman,et al. of its Pharmacological Properties and Therapeutic Use in Acid-Related Disorders , 2012 .
[22] Anders F. Andersson,et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. , 2010, Gastroenterology.
[23] A. Reid,et al. Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding: effect of standardized guidelines on prescribing practice. , 2010, Archives of internal medicine.
[24] William A. Walters,et al. QIIME allows analysis of high-throughput community sequencing data , 2010, Nature Methods.
[25] Anders F. Andersson,et al. Short-Term Antibiotic Treatment Has Differing Long-Term Impacts on the Human Throat and Gut Microbiome , 2010, PloS one.
[26] S. Eid,et al. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. , 2010, Internal medicine.
[27] B. Roe,et al. A core gut microbiome in obese and lean twins , 2008, Nature.
[28] T. Gill,et al. A standard procedure for creating a frailty index , 2008, BMC geriatrics.
[29] Carlene A. Muto,et al. Antimicrobial-associated risk factors for Clostridium difficile infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] T. Spector,et al. Dietary Patterns and Heritability of Food Choice in a UK Female Twin Cohort , 2007, Twin Research and Human Genetics.
[31] John K Marshall,et al. Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression , 2007, The American Journal of Gastroenterology.
[32] G. Triadafilopoulos,et al. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID‐related gastrointestinal damage , 2005, International journal of clinical practice.
[33] A. Barkun,et al. Meta‐analysis: proton‐pump inhibition in high‐risk patients with acute peptic ulcer bleeding , 2005, Alimentary pharmacology & therapeutics.
[34] D. Castell,et al. Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease , 1999, The American Journal of Gastroenterology.
[35] Miriam C J M Sturkenboom,et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. , 2004, JAMA.
[36] R. Valuck,et al. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. , 2004, Journal of clinical epidemiology.
[37] R. MacLaren,et al. Proton-Pump Inhibitors for Stress Ulcer Prophylaxis in Critically Ill Patients , 2002, The Annals of pharmacotherapy.
[38] Runying Tian,et al. Genome sequence of Streptococcus mutans UA159, a cariogenic dental pathogen , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[39] G. I. Leontiadis,et al. Meta‐analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis , 2001, Alimentary pharmacology & therapeutics.
[40] D. Castell,et al. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease , 1999, American Journal of Gastroenterology.
[41] M. Wilde,et al. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. , 1997, Drugs.
[42] T. Azuma,et al. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. , 1995, Journal of gastroenterology.
[43] D. McTavish,et al. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders. , 1991, Drugs.
[44] H. Satoh,et al. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells , 1993, Antimicrobial Agents and Chemotherapy.
[45] A. Lisbon,et al. ASPIRATION OF GASTRIC BACTERIA IN ANTACID-TREATED PATIENTS: A FREQUENT CAUSE OF POSTOPERATIVE COLONISATION OF THE AIRWAY , 1982, The Lancet.